RAD-150 (TLB-150) 10mg Capsules

Description

What Is RAD-150 (TLB-150)?

RAD-150, also designated TLB-150, is an esterified derivative of RAD-140 (testolone) created by attaching a benzoate ester group to the parent SARM molecule. This chemical modification transforms RAD-140 into a prodrug with enhanced metabolic stability, potentially improved oral bioavailability, and an extended duration of action compared to the unmodified parent compound.

The ester modification follows the same pharmacological strategy used in traditional steroid chemistry, where esterification prolongs absorption and extends the elimination half-life of the active compound. Upon absorption, endogenous esterases cleave the benzoate group, releasing active RAD-140 into systemic circulation. The result is a SARM that delivers the same tissue-selective androgen receptor modulation as testolone but with a modified pharmacokinetic profile that may offer more sustained plasma concentrations and potentially greater anabolic efficiency per dose. RAD-150 maintains the non-steroidal structure and high selectivity ratio of its parent compound while adding the convenience of a longer-acting formulation.

Key Features and Specifications

Mechanism of Action: How RAD-150 Works

RAD-150 functions as a prodrug of RAD-140. After oral administration, the benzoate ester bond is hydrolyzed by endogenous carboxylesterases in the gastrointestinal tract and liver, liberating the active RAD-140 molecule. The released testolone then binds to androgen receptors in skeletal muscle and bone tissue as a full agonist while acting as an antagonist or partial agonist in androgenic tissues such as the prostate, maintaining the tissue-selective profile established by the parent compound.

The ester modification alters the pharmacokinetic properties in several key ways. The benzoate group increases lipophilicity, potentially enhancing membrane permeability and oral absorption. The requirement for enzymatic cleavage before the active compound reaches systemic circulation creates a sustained-release effect, producing more gradual peak plasma concentrations and an extended elimination phase compared to unmodified RAD-140.

Once liberated, the active RAD-140 component recruits tissue-specific coactivator proteins at the androgen receptor, driving anabolic gene expression in myocytes and osteoblasts while sparing androgenic tissues. The compound does not undergo aromatization to estrogen, maintaining the same estrogen-neutral profile as its parent compound.

Reported Research Applications and Benefits

Extended-duration anabolic research represents the primary application for RAD-150 over its parent compound. The modified pharmacokinetic profile may reduce peak-to-trough plasma fluctuations, providing more consistent androgen receptor occupancy throughout the dosing interval. This characteristic is particularly valuable in research designs where stable receptor activation is critical to outcome measurements.

Comparative pharmacokinetic studies between RAD-150 and RAD-140 represent a significant research application, allowing investigators to evaluate how ester modifications affect bioavailability, tissue distribution, receptor binding kinetics, and downstream anabolic outcomes. Lean mass accretion research with RAD-150 leverages the same potent anabolic mechanisms characterized in RAD-140 studies, with the added variable of modified drug release kinetics.

Prodrug design research uses RAD-150 as a case study in ester-based prodrug development for non-steroidal SARMs, investigating how chemical modifications to the parent molecule affect metabolic stability, first-pass metabolism, and overall pharmacological efficiency.

RAD-150 Dosage Information for Research

RAD-150 vs RAD-140: Key Differences

Storage and Handling Instructions

Store RAD-150 capsules at controlled room temperature between 20°C and 25°C (68°F to 77°F) in the original sealed container. Protect from direct sunlight, excessive heat, and moisture. Under recommended conditions, RAD-150 capsules maintain full potency for at least 24 months from manufacture. Avoid prolonged exposure to temperatures above 30°C.

Why Choose PrymaLab RAD-150 TLB-150 Capsules

Every batch of PrymaLab RAD-150 undergoes comprehensive third-party analysis by independent, accredited laboratories using HPLC for purity verification and mass spectrometry for structural identity confirmation, including verification of the intact ester bond. Each order includes a batch-specific Certificate of Analysis documenting ≥99% purity, heavy metal screening, residual solvent analysis, and microbial testing results. Pharmaceutical-grade encapsulation ensures precise 10 mg dosing, and free priority shipping is included on domestic orders.

Frequently Asked Questions About RAD-150

What is the difference between RAD-150 and RAD-140?

RAD-150 is a benzoate ester prodrug of RAD-140. The ester group is cleaved after absorption, releasing the same active RAD-140 molecule. The key differences are pharmacokinetic: RAD-150 may offer enhanced oral absorption due to increased lipophilicity and an extended duration of action due to the sustained-release effect of ester hydrolysis.

Does RAD-150 convert to RAD-140 in the body?

Yes. RAD-150 is a prodrug that requires enzymatic hydrolysis to release its active component. Endogenous carboxylesterases in the GI tract and liver cleave the benzoate ester bond, liberating RAD-140 (testolone) into systemic circulation. All downstream pharmacological effects are mediated by the released RAD-140 molecule.

Does RAD-150 require post-cycle therapy?

Yes. Because RAD-150 releases RAD-140 as its active metabolite, it carries the same suppressive potential as the parent compound. Research protocols lasting eight weeks or longer typically incorporate post-cycle therapy using SERMs. Comprehensive blood panels before and after research protocols are recommended.

Is RAD-150 more potent than RAD-140?

RAD-150 is not inherently more potent than RAD-140 because the active molecule is identical. The differences lie in pharmacokinetics: RAD-150 may deliver more sustained plasma concentrations and potentially improved bioavailability, which could enhance overall anabolic efficiency per dose without changing the intrinsic potency at the androgen receptor.

What is the half-life of RAD-150?

The precise plasma half-life of RAD-150 has not been established in published clinical pharmacokinetic studies. Based on the ester prodrug mechanism, RAD-150 is expected to have an extended duration of action compared to RAD-140 (which has a ~60-hour half-life in primates), as the ester hydrolysis step creates a sustained-release profile.

Quality Assurance and Testing

PrymaLab maintains rigorous quality standards for all RAD-150 products. Each batch is independently tested using HPLC purity analysis with verification of the intact ester bond, mass spectrometry identity confirmation, heavy metal screening, residual solvent testing, and microbial assessment. Batch-specific Certificates of Analysis are provided with every order for complete analytical transparency.

Research Disclaimer

RAD-150 (TLB-150) is sold strictly for laboratory research and scientific investigation purposes only. This product is not intended for human consumption, veterinary use, or therapeutic application. RAD-150 has not been approved by the FDA or any regulatory agency for medical use. Purchasers must be qualified researchers affiliated with accredited institutions or licensed research organizations. By purchasing this product, you confirm that it will be used exclusively in accordance with all applicable local, state, and federal regulations governing research materials.